The more recent understanding that both of these agents display extremely high response rates in patients harboring somatic mutations in EGFR has resulted in the first molecularly stratified licensing approval for a drug in NSCLC[12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.